Stock Analiz

Autolus Therapeutics plc AUTL

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026

$1.17Market cap $312M
Open the interactive analysis →

Autolus Therapeutics plc (AUTL) is a healthcare company listed in the US with a market value of about $312M. In the twelve months to September 30, 2026 it had revenue of $137M and net income of -$256M, a net margin of -186.4%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -61%.

About Autolus Therapeutics

Autolus Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. It was profitable in 0 of the last 6 years in our data. It spends 156% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.3
P/B11.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-57.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)644.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4944.7%
ROIC (5-yr avg.)-60.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$137M$75M$10M$2M———
Net income-$256M-$288M-$221M-$208M-$149M-$142M-$142M
Free cash flow-$180M-$303M-$228M-$157M-$123M-$127M-$132M
EPS (diluted)$-0.97$-1.08$-0.83$-0.78$-0.56$-0.53$-0.53
Net margin-186.4%-381.4%-2180.5%-12272.3%———
ROIC—-85.7%-39.7%-109.3%-35.1%-33.3%-54.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $8.36, 615% above the current price; targets range from $5.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.80 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Autolus Therapeutics pay a dividend?

Not currently.

Is Autolus Therapeutics a good stock to buy?

We do not give buy or sell advice. Autolus Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.